Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

G Klement, S Baruchel, J Rak, S Man… - The Journal of …, 2000 - Am Soc Clin Investig
Various conventional chemotherapeutic drugs can block angiogenesis or even kill activated,
dividing endothelial cells. Such effects may contribute to the antitumor efficacy of …

Photo elicitation interview (PEI): Using photos to elicit children's perspectives

…, P McKeever, S Baruchel - International journal of …, 2006 - journals.sagepub.com
When conducting photo elicitation interviews (PEI), researchers introduce photographs into
the interview context. Although PEI has been employed across a wide variety of disciplines …

Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction

B Das, R Tsuchida, D Malkin, G Koren, S Baruchel… - Stem …, 2008 - academic.oup.com
Although advances have been made in understanding the role of hypoxia in the stem cell
niche, almost nothing is known about a potentially similar role of hypoxia in maintaining the …

Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study

…, C Hawkins, J Hitzler, JCY Wang, S Baruchel… - The lancet …, 2013 - thelancet.com
Background Identification of robust biomarkers of malignancy and methods to establish
disease progression is a major goal in paediatric neuro-oncology. We investigated whether …

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study

…, PC Adamson, JM Reid, L Xu, S Baruchel… - Journal of clinical …, 2008 - ascopubs.org
Purpose We conducted a pediatric phase I trial of the vascular endothelial growth factor (VEGF)–neutralizing
antibody bevacizumab (BV). Primary aims included estimating the …

[PDF][PDF] Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma

…, D Stephens, U Tabori, S Baruchel - Journal of clinical …, 2012 - academia.edu
… Eric Bouffet, Regina Jakacki, Stewart Goldman, Darren Hargrave, Cynthia Hawkins,
Manohar Shroff, Juliette Hukin, Ute Bartels, Nicholas Foreman, Stewart Kellie, Joanne …

The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus

S Baruchel, MA Wainberg - Journal of leukocyte biology, 1992 - academic.oup.com
This review describes the potential role of oxidative stress as a cofactor of disease
progression from asymptomatic human immunodeficiency virus (HIV) infection to the acquired …

Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group …

…, A Lee, JM Reid, S Baruchel… - Journal of clinical …, 2013 - ascopubs.org
Purpose Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free
survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic and …

[PDF][PDF] Whey proteins as a food supplement in HIV-seropositive individuals

S Baruchel, G Bounous, J Falutz… - Clin Invest …, 1993 - xn--vivetussueoshoy-7qb.com
On the basis of numerous animal experiments, a pilot study was undertaken to evaluate the
effect of undenatured, biologically active, dietary whey protein in 3 HIV-seropositive …

Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial

…, D Stephens, M Weinstein, N Ho, S Baruchel - …, 2007 - publications.aap.org
OBJECTIVES. Oral systemic corticosteroids are the mainstay of treatment for problematic
hemangiomas; however, current information is based on anecdotal experience and …